welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia
source: Cancer Prevention Research
year: 2017
authors: Don A. Delker, Austin C. Wood, Angela K. Snow, N. Jewel Samadder, Wade S. Samowitz, Kajsa E. Affolter, Kenneth M. Boucher, Lisa M. Pappas, Inge J. Stijleman, Priyanka Kanth , Kathryn R. Byrne, Randall W. Burt, Philip S. Bernard, Deborah W. Neklason
summary/abstract:Abstract
To identify gene expression biomarkers and pathways targeted by sulindac and erlotinib given in a chemoprevention trial with a significant decrease in duodenal polyp burden at 6 months (P < 0.001) in familial adenomatous polyposis (FAP) patients, we biopsied normal and polyp duodenal tissues from patients on drug versus placebo and analyzed the RNA expression. RNA sequencing was performed on biopsies from the duodenum of FAP patients obtained at baseline and 6-month endpoint endoscopy. Ten FAP patients on placebo and 10 on sulindac and erlotinib were selected for analysis. Purity of biopsied polyp tissue was calculated from RNA expression data. RNAs differentially expressed between endpoint polyp and paired baseline normal were determined for each group and mapped to biological pathways. Key genes in candidate pathways were further validated by quantitative RT-PCR. RNA expression analyses of endpoint polyp compared with paired baseline normal for patients on placebo and drug show that pathways activated in polyp growth and proliferation are blocked by this drug combination. Directly comparing polyp gene expression between patients on drug and placebo also identified innate immune response genes (IL12 and IFNg) preferentially expressed in patients on drug. Gene expression analyses from tissue obtained at endpoint of the trial demonstrated inhibition of the cancer pathways COX2/PGE2, EGFR, and WNT. These findings provide molecular evidence that the drug combination of sulindac and erlotinib reached the intended tissue and was on target for the predicted pathways. Furthermore, activation of innate immune pathways from patients on drug may have contributed to polyp regression.
DOI: 10.1158/1940-6207.CAPR-17-0130
read more
expertly curated content related to this topic
-
Despite Promise, Vitamin D and Calcium do not Reduce Colorectal Cancer RiskThe New England Journal of Medicine repo...
-
Restorative Proctectomy with Ileal Pouch-Anal Anastomosis in Obese PatientsPURPOSE : The aim of this study was to a...
-
Stages and Evaluation of Surgical Innovation: A Clinical Example of the Ileo Neo Rectal Anastomosis After Ulcerative...AIM: So far, not many clinical examples...
-
Diagnosis, Surveillance, and Treatment Strategies For Familial Adenomatous Polyposis: Rationale and UpdateFamilial adenomatous polyposis is charac...
-
Chemoprevention in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) pre...
-
Ostomy LifeOstomy Life...